Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well [Seeking Alpha]
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: Seeking Alpha
Zynquista's renewed FDA engagement for Type 1 diabetes could enable resubmission in early 2026, but commercial execution and reimbursement remain key hurdles. Inpefa's HCM Phase III readout is expected in Q1'27, yet LXRX's solo commercialization strategy is questionable without a partner or capital raise. Pilavapadin's Phase III prospects hinge on improved efficacy, tolerability, and/or differentiation vs. generics, but data so far have been mixed; partnership will be crucial for commercial success. Any of these three opportunities could support a fair value of $6-plus, but the odds seem long for all of them, and LXRX would need significantly more cash to commercialize any of them alone. Trevor Williams/DigitalVision via Getty Images The Lexicon Pharmaceuticals, Inc. ( LXRX ) story has had quite a few twists and turns over the years, but arguably the one constant has been that this tiny biotech can produce drugs that deliver encouraging This article was written by Analy
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor ConferencesGlobeNewswire
- Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win [Seeking Alpha]Seeking Alpha
- Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare ConferenceGlobeNewswire
LXRX
Earnings
- 11/6/25 - Beat
LXRX
Sec Filings
- 11/10/25 - Form 8-K
- 11/6/25 - Form 424B5
- 11/6/25 - Form 8-K
- LXRX's page on the SEC website